Spero
Cambridge, US · 1 known investors
Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.
Investors · 1
Frequently asked questions
- What does Spero do?
- Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.
- Who are Spero's investors?
- Spero's investors include HEALTHCARE ROYALTY PARTNERS.
- Where is Spero headquartered?
- Spero is headquartered in Cambridge, US.